[2-Chloro-4-(3-chloro-phenyl)-quinolin-6-yl]-(4-chloro-phenyl)-methanone | 280144-85-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: [2-Chloro-4-(3-chloro-phenyl)-quinolin-6-yl]-(4-chloro-phenyl)-methanone
• 英文别名: [2-Chloro-4-(3-chlorophenyl)quinolin-6-yl]-(4-chlorophenyl)methanone
• CAS: 280144-85-6
• 化学式: C₂₂H₁₂Cl₃NO
• 分子量: 412.702
• InChiKey: MDURLVPDVHJULR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [2-Chloro-4-(3-chloro-phenyl)-quinolin-6-yl]-(4-chloro-phenyl)-methanone 在 正丁基锂 、 肼 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 生成 (4-Chlorophenyl)-[4-(3-chlorophenyl)-2-hydrazinylquinolin-6-yl]-(3-methylimidazol-4-yl)methanol
  参考文献：
  名称：

  Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors

  摘要：

  A series of (4-chlorophenyl)-alpha-(1-methyl-1H-imidazol-5-yl)azoloquinolines and -quinazolines was prepared. These compounds displayed potent Farnesyl Protein Transferase inhibitory activity and tetrazolo[1,5-a]quinazolines are promising agents for oral in vivo inhibition. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.080
• 作为产物：
  描述：

  N-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide 在 potassium tert-butylate 、 三氯氧磷 作用下， 以 乙二醇二甲醚 为溶剂， 生成 [2-Chloro-4-(3-chloro-phenyl)-quinolin-6-yl]-(4-chloro-phenyl)-methanone
  参考文献：
  名称：

  Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors

  摘要：

  A series of (4-chlorophenyl)-alpha-(1-methyl-1H-imidazol-5-yl)azoloquinolines and -quinazolines was prepared. These compounds displayed potent Farnesyl Protein Transferase inhibitory activity and tetrazolo[1,5-a]quinazolines are promising agents for oral in vivo inhibition. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.080

文献信息

• 1,2-annelated quinoline derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US20030119843A1

  公开（公告）日：2003-06-26

  This invention concerns compounds of formula 1 the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein ═X 1 —X 2 —X 3 — is a trivalent radical,; >Y 1 —Y 2 — is a trivalent radical; r and s are each independently 0, 1, 2, 3, 4 or 5; t is 0, 1, 2 or 3; each R 1 and R 2 are independently hydroxy, halo, cyano, C 1-6 alkyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkyloxyC 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, aminoC 1-6 alkyloxy, mono- or di(C 1-6 alkyl)amino, mono- or di(C 1-6 alkylaminoC 1-6 alkyloxy, aryl, arylC 1-6 alkyl, aryloxy or arylC 1-6 alkyloxy, hydroxycarbonyl, C 1-6 alkyloxycarbonyl; or two R 1 or R 2 on adjacent positions form together a bivalent radical; R 3 is hydrogen, halo, C 1-6 alkyl, cyano, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, cyanoC 1-6 alkyl, aminoC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, C 1-6 alkylthio-C 1-6 alkyl, aminocarbonylC 1-6 alkyl, hydroxycarbonyl, hydroxycarbonylC 1-6 alkyl, C 1-6 alkyoxycarbonylC 1-6 alkyl, C 1-6 alkylcarbonylC 1-6 alkyl, C 1-6 alkyloxycarbonyl, aryl, arylC 1-6 alkyloxyC 1-6 alkyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, or a radical of formula —O—R 10 , —S—R 10 or —NR 11 R 12 ; R 4 is an optionally substituted imidazolyl; aryl is an optionally substituted phenyl or naphthalenyl; having farnesyl transferase and geranylgeranyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及公式1的化合物及其药学上可接受的酸盐和立体化学异构体，其中═X1—X2—X3—是三价基团; >Y1—Y2—是三价基团; r和s分别独立地为0、1、2、3、4或5; t为0、1、2或3; 每个R1和R2独立地为羟基、卤素、氰基、C1-6烷基、三卤甲基、三卤甲氧基、C2-6烯基、C1-6烷氧基、羟基C1-6烷氧基、C1-6烷基硫基、C1-6烷氧基C1-6烷氧基、C1-6烷氧基羰基、氨基C1-6烷氧基、单-或双(C1-6烷基)氨基、单-或双(C1-6烷基氨基C1-6烷氧基、芳基、芳基C1-6烷基、芳氧基或芳基C1-6烷氧基、羟基羧酸、C1-6烷氧羧酸; 或者相邻位置的两个R1或R2结合成一个二价基团; R3是氢、卤素、C1-6烷基、氰基、卤素C1-6烷基、羟基C1-6烷基、氰基C1-6烷基、氨基C1-6烷基、C1-6烷氧基C1-6烷基、C1-6烷基硫基-C1-6烷基、氨基羧酰基C1-6烷基、羟基羧酰基、羟基羧酰基C1-6烷基、C1-6烷氧羧酸C1-6烷基、C1-6烷基羧酰基C1-6烷基、C1-6烷氧羰基、芳基、芳基C1-6烷氧基C1-6烷基、单-或双(C1-6烷基)氨基C1-6烷基，或者是公式—O—R10、—S—R10或—NR11R12的基团; R4是可选择取代的咪唑基; 芳基是可选择取代的苯基或萘基; 具有法尼酰转移酶和戊二烯基戊二酰转移酶抑制活性; 它们的制备、含有它们的组合物以及它们作为药物的用途。
• 4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the Farnesyltransferase inhibitor ZARNESTRA ™
  作者：Patrick Angibaud、Ashis K. Saha、Xavier Bourdrez、David W. End、Eddy Freyne、Patricia Lezouret、Geert Mannens、Laurence Mevellec、Christophe Meyer、Isabelle Pilatte、Virginie Poncelet、Bruno Roux、Gerda Smets、Jacky Van Dun、Marc Venet、Walter Wouters

  DOI：10.1016/j.bmcl.2003.09.043

  日期：2003.12

  Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA(TM) series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition. (C) 2003 Elsevier Ltd. All rights reserved.
• 1,2-ANNELATED QUINOLINE DERIVATIVES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1140935A2

  公开（公告）日：2001-10-10
• US6458800B1
  申请人：——

  公开号：US6458800B1

  公开（公告）日：2002-10-01
• US6914066B2
  申请人：——

  公开号：US6914066B2

  公开（公告）日：2005-07-05